Lupin Limited has announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, marking an important addition to its diabetes care portfolio. The product is available in four strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg.
The launch follows approval of the company’s Abbreviated New Drug Application by the US Food and Drug Administration. The formulation has been approved as bioequivalent to Xigduo XR for use in line with the approved prescribing information.
This development underscores Lupin’s continued focus on expanding its presence in the United States, one of its key markets, while addressing the growing burden of diabetes through accessible and effective treatment options. By introducing this combination therapy, the company aims to support healthcare providers and patients with a reliable alternative that combines two widely used anti-diabetic agents in a single extended-release formulation.
Headquartered in Mumbai, Lupin Limited is recognized as a major global pharmaceutical company with a presence across more than 100 markets. The organization has built a diversified portfolio spanning branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The company maintains a strong position in both India and the United States across multiple therapeutic segments. These include respiratory care, cardiovascular treatments, diabetes management, anti-infectives, gastrointestinal therapies, central nervous system disorders, and women’s health. Its broad capabilities enable it to address a wide range of patient needs while maintaining a focus on quality and compliance.
Lupin operates an extensive global manufacturing and research network, comprising 15 advanced production facilities and seven research centers. This infrastructure is supported by a workforce of over 24,000 professionals dedicated to innovation, quality, and operational excellence.
In addition to its core pharmaceutical business, Lupin continues to expand its healthcare ecosystem through its subsidiaries, including Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. These initiatives reflect the company’s commitment to enhancing patient outcomes by integrating diagnostics, digital platforms, and manufacturing expertise.